Research programme: retinoid X receptor agonists - Connexios

Drug Profile

Research programme: retinoid X receptor agonists - Connexios

Alternative Names: CNX 013; CNX 016; CNX 017; CNX-013-B2; CNX-015; CNX-018; CNXFC 010; RXR agonists - Connexios

Latest Information Update: 09 May 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Connexios Life Sciences
  • Class Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor agonists; Retinoid X receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Dyslipidaemias; Type 2 diabetes mellitus

Most Recent Events

  • 09 May 2014 Preclinical development is ongoing in India
  • 09 May 2014 This programme appears to remain available for licensing as of 09 May 2014.
  • 20 Oct 2009 Preclinical trials in Type-2 diabetes mellitus in India (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top